Welcome to Sanofi
Committed to discovering, developing and distributing therapeutic solutions to improve the lives of everyone, Sanofi is a leading global pharmaceutical company. Number 1 in Europe, the Group is present in more than 100 countries and is growing rapidly. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY) and has one of the largest market capitalizations in Paris.
Welcome to Sanofi in Hong Kong
Every year, the Group spent about one sixth (15%) of its sales revenue into Research & Development. In 2006, the Group invested 4.4 billion euros out of its net sales of 28.4 billion euros.
With a portfolio containing a wide range of innovative vaccines and medicines, sanofi-aventis excels in the areas of Thrombosis, Diabetes, Cardiovascular diseases, Oncology, disorders of the Central Nervous System, Vaccines and Internal Medicine.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases.
The Company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us.
If you would like more information than what we can provide here on any aspect of our work, please contact us.
August 06, 2015
Sanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies
- Download (PDF, 66Kb)
July 31, 2015
Online Availability of Sanofi Group’s Half-Year Financial Report for 2015
- Download (PDF, 138Kb)
July 30, 2015
Sanofi delivers solid sales and business EPS growth in Q2 2015
- Download (PDF, 1051Kb)
July 29, 2015
Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint
- Download (PDF, 213Kb)